Table 1.
Baseline Patient & Disease Characteristics
| VRd (n=542) | KRd (n=545) | ||
|---|---|---|---|
| Age (y) | 64 (57–71) | 65 (59–71) | |
| >/=70 years | 167 (31%) | 177 (33%) | |
| Time from Diagnosis (wks) | 3 (2–4) | 3 (2–4) | |
| Gender | Male | 315 (58%) | 327 (60%) |
| Female | 227 (42%) | 218 (40%) | |
| Race | White | 443 (85%) | 448 (86%) |
| Black | 68 (13%) | 59 (11%) | |
| Other | 13 (2%) | 12 (2%) | |
| Missing/Unk | 18 | 26 | |
| Non-White | 81 (15%) | 71 (14%) | |
| ECOG PS | PS0 | 212 (39%) | 241 (44%) |
| PS1 | 270 (50%) | 249 (46%) | |
| PS2 | 50 (9%) | 45 (8%) | |
| PS3 | 10 (2%) | 10 (2%) | |
| PS>0 | 330 (61%) | 304 (56%) | |
| Intent to Transplant at PD | Yes | 396 (73.1) | 398 (73.0) |
| ISS Stage | I | 213 (39%) | 184 (34%) |
| II | 188 (35%) | 199 (37%) | |
| III | 138 (26%) | 159 (29%) | |
| Missing | 3 | 3 | |
| I-II | 401 (74%) | 383 (71%) | |
| Measurable Disease Type | SPEP&UPEP | 115 (21%) | 114 (21%) |
| SPEP | 305 (56%) | 296 (54%) | |
| UPEP | 57 (11%) | 79 (14%) | |
| FLC | 58 (11%) | 51 (9%) | |
| Bone Marrow | 4 (<1%) | 4 (<1%) | |
| Not Measurable | 3 (<1%) | 1 (<1%) | |
| Cytogenetics* | Normal | 326 (72%) | 331 (72%) |
| Abnormal | 128 (28%) | 127 (28%) | |
| Missing | 88 | 67 | |
| FISH | Normal | 115 (21%) | 115 (21%) |
| Abnormal | 423 (79%) | 427 (79%) | |
| Missing | 4 | 3 | |
| Plasma cell (%) | 52 (30–75) | 51 (30–72) | |
| Missing | 8 | 3 | |
| Albumin (g/dL) | 3·8 (3·4–4·2) | 3·8 (3·4–4·2) | |
| Missing | 1 | 2 | |
| Beta2microglobulin (ug/mL) | 3·6 (2·6–5·6) | 3·9 (2·8–6) | |
| Missing | 2 | 1 | |
| Hemoglobin (g/dL) | 11·0 (9·6–12·4) | 11·2 (9·8–12·6) | |
| Calcium (mg/dL) | 9·3 (8·9–9·8) | 9·4 (8·9–9·8) | |
| Missing | 1 | 0 | |
^
Data are median (IQR) or N (%); Missing data are excluded from calculations
*
Metaphase cytogenetics was considered positive in the presence of any abnormality